CHI3L1 and neoplasm: From a therapeutic standpoint, CHI3L1 inhibition may suppress tumor growth, and therapeutic strategies, including anti-CHI3L1 monoclonal antibodies and bispecific antibodies targeting CHI3L1/PD-1, are currently under development (Figure 1) [37,57].